Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 17, Issue 8, Pages 2617-2625Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2021.1893036
Keywords
Immunotherapy; cervical cancer; listeria monocytogenes vaccine
Categories
Ask authors/readers for more resources
ADXS11-001 is an immunotherapy based on live attenuated Listeria monocytogenes designed to treat HPV-associated cancers. It works by secreting a fusion protein that activates specific CTLs to destroy HPV-infected cells within the body.
Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (Lm-LLO), designed by biological engineering to secrete an antigen-adjuvant fusion protein, composed of a truncated fragment of LLO fused to HPV. The proposed mechanism of action is that Lm-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available